Abstract

HbA1c is a major test in the medical laboratory because the test result is of conclusive relevance for diagnosis and treatment of diabetes, a high prevalence chronic disease. Therefore, the quality of the test is of utmost clinical importance. The impact of bias and imprecision will be discussed and requirements for diagnosis and monitoring treatment be derived from the IFCC model for quality targets.

To demonstrate the present status of HbA1c tests, the outcome of EurA1c, the international PT trial with participation of more than 5000 labs in 20 countries will be shown.

Speaker

Dr. Cas WEYKAMP
Clinical Chemist and Director of the MCA laboratory of the Queen Beatrix Hospital, Winterswijk, The Netherlands

Do you have questions about this webinar?

Contact us